Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Immune Thrombocytopenia (ITP) Immune-Genetic Assessment (UNIT)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified September 2010 by Azienda Ospedaliero Universitaria Udine, SOC Clinica Ematologica.
Recruitment status was:  Not yet recruiting
Information provided by:
Azienda Ospedaliero Universitaria Udine, SOC Clinica Ematologica Identifier:
First received: September 7, 2010
Last updated: September 8, 2010
Last verified: September 2010

Primary ITP has wide heterogenous biology, presentation and response to therapy.

The immune-genetic assessment of ITP may help to identify differences among patients with ITP and optimize the therapeutic choice.


Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective

Resource links provided by NLM:

Further study details as provided by Azienda Ospedaliero Universitaria Udine, SOC Clinica Ematologica:

Estimated Enrollment: 190
Study Start Date: September 2010
Asymptomatic ITP patients
ITP patients treated with Rituximab
ITP patients treated with steroids


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Primary care clinic

Inclusion Criteria:

  • Adult patients with primary ITP

Exclusion Criteria:

  • Secondary ITP
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01196884

Istituto di Ematologia L. & A. Seragnoli
Bologna, Italy, 40100
Department of Hematology and Bone Marrow Transplantation Unit, Oncology Center Armando Businco
Cagliari, Italy, 09100
UF Ematologia, Policlinico di Careggi
Firenze, Italy
U.O. Ematologia 2, IRCCS Cà Granda Ospedale Maggiore Policlinico
Milano, Italy, 20122
Department of Oncology/Haematology, Niguarda Ca'Granda Hospital
Milano, Italy
Clinica Ematologica, Dipartimento di Medicina Clinica e Sperimentale, Università degli Studi del Piemonte Orientale "Amedeo Avogadro
Novara, Italy, 28100
Istituto di Immunologia, Dipartimento di Scienze Mediche dell'Università degli Studi del Piemonte Orientale "Amedeo Avogadro"
Novara, Italy, 28100
Department of Medical and Surgical Sciences, University of Padova
Padova, Italy, 35100
Oncology-Hematology Department, "S. Maria delle Croci" Hospital
Ravenna, Italy, 48121
Institute of Hematology, Catholic University,
Roma, Italy, 00168
Ematologia, Ospedale Ca' Foncello
Treviso, Italy, 31100
Clinica Ematologica AOUD S. Maria Misericordia
Udine, Italy, 33100
Ematologia, San Bortolo Hospital
Vicenza, Italy, 36100
Sponsors and Collaborators
Azienda Ospedaliero Universitaria Udine, SOC Clinica Ematologica
  More Information

Responsible Party: Francesco Zaja, Clinica Ematologica, Azienda Ospedaliero Universitaria S. Maria Misericordia di Udine Identifier: NCT01196884     History of Changes
Other Study ID Numbers: UNIT 
Study First Received: September 7, 2010
Last Updated: September 8, 2010
Health Authority: Italy: Ministero della Salute

Keywords provided by Azienda Ospedaliero Universitaria Udine, SOC Clinica Ematologica:
Patients with primary Immune Thrombocytopenia (ITP)

Additional relevant MeSH terms:
Purpura, Thrombocytopenic, Idiopathic
Blood Platelet Disorders
Hematologic Diseases
Purpura, Thrombocytopenic
Blood Coagulation Disorders
Thrombotic Microangiopathies
Hemorrhagic Disorders
Autoimmune Diseases
Immune System Diseases
Pathologic Processes
Skin Manifestations
Signs and Symptoms processed this record on January 14, 2017